Navigation Links
Frost & Sullivan Lauds SonoScape's Outstanding Entrepreneurship
Date:1/6/2009

and revolutionary product solution with significant market potential. Additionally, the Award certifies that the company's marketing strategy is sound and poised for success.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About SonoScape

SonoScape Company Limited is a high-tech enterprise specializing in developing and manufacturing digital color Doppler ultrasound systems and ultrasound transducers. SonoScape has successfully developed and put into mass production ten different models of digital color Doppler ultrasound systems, and 50 types of various high density ultrasound probes for applications of cardiac, general purpose, OB/GYN, etc.

SonoScape has a state-of-the-art production line for building leading-edge Digital Color Doppler ultrasound systems and high performance high density ultrasound probes. The annual output for Color Ultrasound system is 2000 units and 10000 pieces of ultrasound probes. The full range of SonoScape's ultrasound scanners are FDA cleared, CE marked and China SFDA certified.

SonoScape has been participating in the national and international medical exhibitions every year, such as MEDICA in Dusseldorf, Germany and RSNA in Chicago, USA. SonoScape's Color Doppler ultrasound systems have been exporting to more than eighty countries in Europe, USA, Middle East, South America and Eastern Europe.

SonoScape Development Milestones:

  • 2003: SonoScape released the world's first full function larg
    '/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Treatment Programs Benefit Depressed Workers 2Health News:Treatment Programs Benefit Depressed Workers 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 2Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 4Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 2Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 3Health News:AHF Launches 'Public Health Division' 2Health News:AHF Launches 'Public Health Division' 3Health News:AHF Launches 'Public Health Division' 4Health News:'Making the Case:' special double issue of Critical Inquiry 2Health News:'Making the Case:' special double issue of Critical Inquiry 3Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2